Universität zu Köln

Neuhaus, Oliver, Koehler, Wolfgang, Then Bergh, Florian, Kristoferitsch, Wolfgang ORCID: 0000-0002-5734-9364, Faiss, Juergen, Rosenkranz, Thorsten, Reske, Dirk ORCID: 0000-0003-0950-1912, Patejdl, Robert ORCID: 0000-0003-4587-4054, Hartung, Hans-Peter and Zettl, Uwe K. (2021). Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers. Biomolecules, 11 (3). BASEL: MDPI. ISSN 2218-273X

Full text not available from this repository.

Abstract

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial effects on MS fatigue. The objective of this study was to correlate clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. In a prospective, open-label, multicenter trial, 30 patients with RRMS and fatigue were treated with GA for 12 months. Inclusion criterion was the presence of fatigue as one of the most frequent and disabling symptoms. Before and during treatment, fatigue was assessed using the Fatigue Severity Scale (FSS), the MS-FSS, and the Modified Fatigue Impact Scale (MFIS). In addition, fatigue and quality of life were assessed using the Visual Analog Scales (VAS). Laboratory assessments included screening of 188 parameters using real-time PCR microarrays followed by further analysis of several cytokines, chemokines, and neurotrophic factors. Fatigue self-assessments were completed in 25 patients. After 12 months of treatment with GA, 13 of these patients improved in all three scales (with the most prominent effects on the MFIS), whereas 5 patients had deteriorated. The remaining 7 patients exhibited inconsistent effects within the three scales. Fatigue and overall quality of life had improved, as assessed via VAS. Laboratory assessments revealed heterogeneous mRNA levels of cytokines, chemokines, and neurotrophic factors. In conclusion, we were not able to correlate clinical and molecular effects of GA in patients with RRMS and fatigue.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Neuhaus, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Koehler, Wolfgang UNSPECIFIED UNSPECIFIED UNSPECIFIED Then Bergh, Florian UNSPECIFIED UNSPECIFIED UNSPECIFIED Kristoferitsch, Wolfgang UNSPECIFIED orcid.org/0000-0002-5734-9364 UNSPECIFIED Faiss, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenkranz, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Reske, Dirk UNSPECIFIED orcid.org/0000-0003-0950-1912 UNSPECIFIED Patejdl, Robert UNSPECIFIED orcid.org/0000-0003-4587-4054 UNSPECIFIED Hartung, Hans-Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Zettl, Uwe K. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-599497
DOI:	10.3390/biom11030393
Journal or Publication Title:	Biomolecules
Volume:	11
Number:	3
Date:	2021
Publisher:	MDPI
Place of Publication:	BASEL
ISSN:	2218-273X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DOUBLE-BLIND; CELL-LINES; MANAGEMENT; DISABILITY; EXPRESSION; THERAPY Multiple languages Biochemistry & Molecular Biology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59949